New Zealand markets closed

Genmab A/S (GMAB)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
42.81+0.53 (+1.25%)
As of 1:22PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close42.28
Open42.61
Bid42.88 x 1300
Ask42.91 x 800
Day's range42.42 - 42.92
52-week range30.10 - 49.07
Volume188,605
Avg. volume479,459
Market cap28.005B
Beta (5Y monthly)0.60
PE ratio (TTM)70.89
EPS (TTM)0.60
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est44.79
  • GlobeNewswire

    Clinical Trial of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory B-cell non-Hodgkin’s Lymphoma (B-NHL) Published in The Lancet

    Media Release Phase 1/2 first-in-human (FIH) dose escalation and cohort expansion trial evaluating safety and preliminary efficacy of epcoritamab in patients with relapsed/refractory B-cell non-Hodgkin’s lymphoma (B-NHL) published in The LancetResults also presented during oral session at the 16th Annual International Conference on Malignant Lymphoma (ICML) and as a poster at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting and the 2021 European Hematology Association (EHA) A

  • GlobeNewswire

    Genmab to Present at Morgan Stanley 19th Annual Global Healthcare Conference

    Media ReleaseCopenhagen, Denmark, 27 August, 2021 Genmab A/S (Nasdaq: GMAB) announced today that its CEO, Jan van de Winkel, Ph.D. will participate in a virtual fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference at 8:00 AM EDT / 2:00 PM CEST on September 9, 2021. A webcast of the event, which will include brief opening remarks followed by a question-and-answer session, will be available on Genmab’s website at https://ir.genmab.com/events-and-presentations#content About

  • GlobeNewswire

    Capital Increase in Genmab as a Result of Employee Warrant Exercise

    Company Announcement COPENHAGEN, Denmark; August 17, 2021 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 12,370 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1: 200 shares at DKK 220.40,1,100 shares at DKK 466.20,200 shares at DKK 623.50,750 shares at DKK 636.50,478 shares